Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trialLore Vanderbeke, Nico Janssen, Dennis C. J. J. Bergmans et al.|Intensive Care Medicine|2021Cited by 98
Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol)Jolien Onsea, Willem‐Jan Metsemakers, Melissa Depypere et al.|Viruses|2021Cited by 50
Predicting Beta-Lactam Target Non-Attainment in ICU Patients at Treatment Initiation: Development and External Validation of Three Novel (Machine Learning) ModelsAndré Wieringa, Alan Abdulla, Tim M. J. Ewoldt et al.|Antibiotics|2023Cited by 7
Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspectiveLaura Bessems, Jolien Onsea, Baixing Chen et al.|Frontiers in Cellular and Infection Microbiology|2024Cited by 4
Exploring the potential of naturally occurring antimicrobials for managing orthopedic-device-related infectionsBaixing Chen, Willem‐Jan Metsemakers, T. Fintan Moriarty et al.|Journal of Bone and Joint Infection|2024Cited by 1